Citation Impact
Citing Papers
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Interferon- γ Control of EBV-Transformed B Cells: A Role for CD8 + T Cells That Poorly Kill EBV-Infected Cells
2002
CDK inhibitors: positive and negative regulators of G1-phase progression
1999 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Expression profiling of murine intestinal adenomas reveals early deregulation of multiple matrix metalloproteinase (Mmp) genes
2005
The p16INK4a/CDKN2A tumor suppressor and its relatives
1998
Megestrol Acetate Stimulates Weight Gain and Ventilation in Underweight COPD Patients
2002
Selection of Patients with Acute Myocardial Infarction for Thrombolytic Therapy
1990
Classification of papillomaviruses
2004 StandoutNobel
Epidermodysplasia Verruciformis: Immunological and Clinical Aspects
1994
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
1998 StandoutNature
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
2002
The HLA crossroad in tumor immunology
2000
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Immunology and immunotherapy of colorectal cancer
2003
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
1998 Standout
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
2001 StandoutNobel
Nasopharyngeal carcinoma
2015 Standout
Deficiency of SPARC suppresses intestinal tumorigenesis in APC Min/+ mice
2007 StandoutNobel
Epstein–Barr virus: 40 years on
2004 Standout
Transporter (TAP)‐independent processing of a multiple membrane‐spanning protein, the Epstein‐Barr virus latent membrane protein 2
1996
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
2012
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
2002 Standout
Calreticulin Promotes Folding of Functional Human Leukocyte Antigen Class I Molecules in Vitro
2004
Optimal utilization of thrombolytic therapy for acute myocardial infarction: Concepts and controversies
1990
MHC class I antigens, immune surveillance, and tumor immune escape
2003
MHC antigens and tumor escape from immune surveillance
2001
Outcome of Patients with Acute Myocardial Infarction Who Are Ineligible for Thrombolytic Therapy
1991
Calreticulin exposure dictates the immunogenicity of cancer cell death
2006 Standout
Second Lung Cancers in Patients After Treatment for an Initial Lung Cancer
1998
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Infection in Organ-Transplant Recipients
1998 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma
2003
Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis
2004
Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product
1996 Nature
Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview
2000 Standout
Epstein–Barr Virus Infection
2000 Standout
The Immunobiology of Cancer Immunosurveillance and Immunoediting
2004 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1
1997 StandoutNobel
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
1998 Standout
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
1994 Standout
CD8+-Cell Antiviral Factor Activity Is Not Restricted to Human Immunodeficiency Virus (HIV)-Specific T Cells and Can Block HIV Replication after Initiation of Reverse Transcription
2000
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Tumor immune escape mechanisms: impact of the neuroendocrine system
2006
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
1999
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
2006
Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response
1997
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
Racial Variation in Cardiac Procedure Use and Survival Following Acute Myocardial Infarction in the Department of Veterans Affairs
1994 Standout
Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro
2003 StandoutNobel
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
2013
Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
2000
Vaccinia Virus Inhibits the Maturation of Human Dendritic Cells: A Novel Mechanism of Immune Evasion
1999 StandoutNobel
HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION
1997
Dendritic Cells Cross-Present Latency Gene Products from Epstein-Barr Virus–Transformed B Cells and Expand Tumor-Reactive Cd8+ Killer T Cells
2001 StandoutNobel
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.
1996
Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation
2003
CD8 T Cell Recognition of Endogenously Expressed Epstein-Barr Virus Nuclear Antigen 1
2004
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
2016
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma
2003
Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization
1997
Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation
2003
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Immunoglobulin G (IgG) and IgA, but also Nonantibody Factors, Account for In Vitro Neutralization of Human Immunodeficiency Virus (HIV) Type 1 Primary Isolates by Serum and Plasma of HIV-Infected Patients
2001 StandoutNobel
Selection Bias in the Use of Thrombolytic Therapy in Acute Myocardial Infarction
1991
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
2008 StandoutNobel
Hepatitis C Virus Envelope Glycoprotein E1 Originates in the Endoplasmic Reticulum and Requires Cytoplasmic Processing for Presentation by Class I MHC Molecules
1999 StandoutNobel
Analysis of prehospital delay among inner-city patients with symptoms of myocardial infarction: implications for therapeutic intervention.
1992
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies
1999
Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
2000 StandoutNobel
The Structure of Anthracycline Derivatives Determines Their Subcellular Localization and Cytotoxic Activity
2013
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Dendritic Cells, Infected with Vesicular Stomatitis Virus-Pseudotyped HIV-1, Present Viral Antigens to CD4+ and CD8+ T Cells from HIV-1-Infected Individuals
2000 StandoutNobel
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Liver-Derived CTL in Hepatitis C Virus Infection: Breadth and Specificity of Responses in a Cohort of Persons with Chronic Infection
1998 StandoutNobel
Works of N. Murray being referenced
Mechanisms of loss of HLA class I expression on colorectal tumor cells
1996
Antigen presentation in virus infection
1992
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
2009
Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes.
1996
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
1995
Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy.
1994
What proportion of patients with myocardial infarction are suitable for thrombolysis?
1987
Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer.
1996